Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib 150 mg versus 300 mg in advanced medullary thyroid carcinoma
2011-004701-24Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vandetanib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Mar 2012; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2011-004701-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004701-24.